The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
13,885
Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date)
Time frame: From randomization to PACD, an average of 2.5 years
Composite of CV Death, MI, Ischemic Stroke, and ALI
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Time frame: From randomization to PACD, an average of 2.5 years
CV Death
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Time frame: From randomization to PACD, an average of 2.5 years
MI
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
All-cause Mortality
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date)
Time frame: From randomization to PACD, an average of 2.5 years
Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date)
Time frame: From randomization to PACD, an average of 2.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Alexander City, Alabama, United States
Research Site
Auburn, Alabama, United States
Research Site
Birmingham, Alabama, United States
Research Site
Birmingham, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Cottonwood, Arizona, United States
Research Site
Mesa, Arizona, United States
Research Site
Phoenix, Arizona, United States
...and 766 more locations
ALI
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
Lower Extremity Revascularization
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years
Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date)
Time frame: From randomization to PACD, an average of 2.5 years